Kylin Therapeutics, Inc. Licenses an RNAi Delivery Technology from Purdue University

WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Purdue Research Foundation announced Monday (July 9) that it has granted Purdue Research Park startup company Kylin Therapeutics Inc., an exclusive license to commercialize a biotechnology that will better target RNA interference (RNAi) delivery technology to combat disease-causing genes.

Back to news